Date: 2016-02-04
Type of information: Distribution agreement
Compound: Fycompa® (perampanel)
Company: Eisai (Japan) Esteve (Spain)
Therapeutic area: Rare diseases - CNS diseases - Neurological diseases
Type agreement: distribution
Action mechanism: AMPA-type glutamate receptor. Fycompa® is a noncompetitive AMPA-type glutamate receptor antagonist discovered and developed by Eisai. This novel chemical entity is an antiepileptic drug that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at postsynaptic AMPA receptors. The agent is currently approved in more than 40 countries and territories, including Europe and the United States, as an adjunctive treatment (once-daily oral dose) of partial-onset seizures.
Disease: adjunctive treatment of primary generalised tonic-clonic (PGTC) seizures in adults and adolescents (?12 years) with idiopathic generalised epilepsy (IGE)
Details: * On February 4, 2016, Eisai announced that the company has entered into a new agreement with Esteve, a Spanish pharmaceutical company with a comprehensive neurology franchise, to co-promote Fycompa® (perampanel) in Spain from February 2016. Eisai and Esteve will launch the new indication for the adjunctive treatment of primary generalised tonic-clonic (PGTC) seizures in adults and adolescents (?12 years) with idiopathic generalised epilepsy (IGE) in Spain in early 2016. Perampanel is also indicated in Spain for the adjunctive treatment of partial onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older.
Financial terms:
Latest news:
